Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday. They presently have a $21.73 price objective on the stock. Vetr‘s price objective would indicate a potential upside of 11.44% from the company’s previous close.
TEVA has been the topic of a number of other reports. Goldman Sachs Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Friday, December 15th. Cantor Fitzgerald set a $18.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, December 28th. BTIG Research set a $16.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Sunday, November 12th. Finally, ValuEngine lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Ten research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eight have issued a buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and an average target price of $20.81.
Teva Pharmaceutical Industries (TEVA) traded up $0.32 during trading on Monday, reaching $19.50. 10,327,591 shares of the company were exchanged, compared to its average volume of 15,890,000. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.86 and a quick ratio of 0.58. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $34.51. The stock has a market cap of $19,620.00, a price-to-earnings ratio of -1.13, a P/E/G ratio of 1.66 and a beta of 0.65.
In related news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at $876,094.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 7,636 shares of company stock worth $149,390. 7.10% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Greylin Investment Mangement Inc. boosted its stake in Teva Pharmaceutical Industries by 36.9% in the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after acquiring an additional 79,300 shares in the last quarter. Exane Derivatives acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $571,000. Korea Investment CORP lifted its stake in shares of Teva Pharmaceutical Industries by 14.3% during the third quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after buying an additional 30,674 shares during the period. Cardinal Capital Management lifted its stake in shares of Teva Pharmaceutical Industries by 4.4% during the third quarter. Cardinal Capital Management now owns 57,624 shares of the company’s stock worth $2,651,000 after buying an additional 2,418 shares during the period. Finally, Financial Counselors Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 5.7% during the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after buying an additional 7,571 shares during the period. Institutional investors own 58.22% of the company’s stock.
WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/03/12/teva-pharmaceutical-industries-teva-downgraded-by-vetr.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.